Eur Rev Med Pharmacol Sci 2019; 23 (9): 3611-3620

DOI: 10.26355/eurrev_201905_17783

MicroRNA-191-5p promotes the development of osteosarcoma via targeting EGR1 and activating the PI3K/AKT signaling pathway

B. Chen, Z.-Y. Zheng, J.-Z. Yang, X.-G. Li

Department of Orthopedics, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. ttbin@zju.edu.cn


OBJECTIVE: MicroRNA-191 (miR-191) has been reported to be abnormally expressed in human cancers and other diseases. The function of miR-191 was contradictory in different cancers. In the present study, we confirmed the specific function of miR-191-5p in osteosarcoma (OS).
PATIENTS AND METHODS: The effects of miR-191-5p on cellular behaviors of OS cells were investigated through MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assay. The quantitative Real-time-polymerase chain reaction (qRT-PCR) was applied to examine the expressions of miR-191-5p and early growth response gene 1 (EGR1). Western blot and immunocytochemical assay were used to detect the protein expression of EGR1. The binding relationship between miR-191-5p and EGR1 was confirmed by Dual-Luciferase reporter gene assay. Xenograft tumor formation assay was conducted to examine the in vivo effect of miR-191-5p on tumor growth of OS.
RESULTS: MiR-191-5p was upregulated in OS tissues, which was related to poor prognosis of OS patients. Moreover, miR-191-5p promoted cell proliferation, migration and invasion by regulating EGR1 in OS. Furthermore, EGR1 was downregulated in OS tissues, which was associated with poor prognosis of OS patients. MiR-191-5p was found to promote epithelial-mesenchymal transition (EMT) and PI3K/AKT pathway, thus promoting the development of OS.
CONCLUSIONS: MiR-191-5p promoted the development of OS via targeting EGR1 and positively regulated the PI3K/AKT signaling pathway.

Free PDF Download

To cite this article

B. Chen, Z.-Y. Zheng, J.-Z. Yang, X.-G. Li
MicroRNA-191-5p promotes the development of osteosarcoma via targeting EGR1 and activating the PI3K/AKT signaling pathway

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 9
Pages: 3611-3620
DOI: 10.26355/eurrev_201905_17783